Doxorubicin and ABT-199 Coencapsulated Nanocarriers for sorted by
relevance

Admin08.09.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

9705
Admin01.10.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

8804
Admin14.07.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

Admin06.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

5206
Admin19.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

8502
Admin06.10.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

4107
Admin16.09.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

3204
Admin29.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

4504
Admin22.07.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

8603
Admin26.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

6106
Admin31.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

4304
Admin18.07.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

9308
Admin14.08.2021

Doxorubicin and ABT-199 Coencapsulated Nanocarriers for

7100
Admin09.09.2021

In Vitro and in Vivo Characterization of Doxorubicin and

Admin04.09.2021

In Vitro and in Vivo Characterization of Doxorubicin and

Admin21.08.2021

Bcl-2 inhibition sensitizes triple-negative human breast

8600
Admin25.09.2021

Overcoming Multidrug Resistance by On-Demand Intracellular

Admin15.08.2021

The Influential Role of BCL2 Family Members in Synovial

8002
Admin16.07.2021

In Vitro and in Vivo Characterization of Doxorubicin and

2003
Admin07.10.2021

Frontiers | Docetaxel and Doxorubicin Codelivery by

9805
Admin15.09.2021

Bcl-2 inhibition sensitizes triple-negative human breast

8404